Testing and Targeting Tumours with RET Alterations
The programme is designed to offer an overview of research activities in this area and review the current status and future prospect of testing and targeting various tumours with RET alterations.
Testing and Targeting Tumours with RET Alterations
Chair: Fabrice Barlesi
Speakers: Frédérique Penault-Llorca, Carmen Belli, Alexander Drilon
Available on demand from 8 October 2020 at 12.00 CEST
*The ESMO Webinar Series is freely available all healthcare professionals working in Oncology
Programme
- Welcome and Introduction, Fabrice Barlesi, Gustave Roussy Cancer Campus, Villejuif, Aix Marseille University, Marseille, France
- How to Provide with RET Testing in Daily Practice?, Frédérique Penault-Llorca, Department of Biopathology, Centre Jean Perrin and University Clermont Auvergne/INSERM U1240, Clermont-Ferrand, France
-
RET Inhibitors: From the Multi Target TKIs to the Highly Specific Inhibitors,
Carmen Belli, Division of Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy - How to Overcome the Mechanisms of Resistance to RET Inhibitors?, Alexander Drilon, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Q&A
- Closing Remarks, Fabrice Barlesi, Gustave Roussy Cancer Campus, Villejuif, Aix Marseille University, Marseille, France
Learning objectives
- To provide an overview of validated methods for the detection of RET gene rearrangements and how to apply them rationally in the clinical practice
- To provide an update on clinical development of RET inhibitors (both unspecified, ie vandetanib, cabozantinib, etc, and specified) across broad range of tumours
- To elaborate how to understand, assess and overcome the mechanisms of resistance to RET inhibitors
Available on demand from 8 October 2020 at 12.00 CEST
*The ESMO Webinar Series is freely available all healthcare professionals working in Oncology
